A phase I study of Triapine [OCX 0191] in combination with radiation therapy in locally advanced pancreas cancer
Latest Information Update: 03 Nov 2021
Price :
$35 *
At a glance
- Drugs OCX 191 (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions
- 17 Aug 2017 Status changed from active, no longer recruiting to completed.
- 04 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 18 Jul 2012 Planned end date changed from 1 Aug 2007 to 1 Jan 2100 as reported by ClinicalTrials.gov